Hannia Bertha Matt-Hernandez

Dr. Hannia Bertha Matt-Hernandez

orcid

Research Focus & Metrics

Representative Publications

View All Publications
30 April 2026 in Sapienza: International Journal of Interdisciplinary Studies
Verified
Journal Article
Open access
MCMadelayne Cecilia Enriquez Cobos
Madelayne Cecilia Enriquez Cobos
SGSofía Alejandra Galvis Garrido
Sofía Alejandra Galvis Garrido
MAMónica Alexandra Caiza Asitimbay
Mónica Alexandra Caiza Asitimbay
HMHannia Bertha Matt-Hernandez
Hannia Bertha Matt-Hernandez
DGDaniel Sebastian Zamora Gutierrez
Daniel Sebastian Zamora Gutierrez
Background: Idiopathic sudden sensorineural hearing loss (ISSNHL) is an otologic emergency with an incidence of 5–27 per 100,000 persons per year. The primary treatment method is corticosteroids, although the most effective way of administration is a controversial issue. The aim of the study is to compare the results of hearing recovery in intratympanic and systemic corticosteroid in ISSNHL. Methods: We used PRISMA to systematically search PubMed, Scopus and Web of Science (2015–2025) to identify randomized controlled trials and prospective comparative studies. The extraction of data was done on the improvement of pure-tone averages, recovery rates and complications. Cochrane RoB 2 was used to assess the risk of bias. Findings: The number of studies and patients included was 17 and 1,649 respectively. In most studies, recovery rates ranged from 60% to 70% across studies. The largest RCT with a 67.3% efficacy rate versus 57.4% with systemic alone (n=47) was combined systemic-intratympanic therapy (n=156) (p>0.05). Salvage intratympanic therapy (n=43) yielded a mean hearing gain of 13.6 dB as compared to no improvement with observation (n=48). Such prognostic variables as vertigo (p=0.039), cardiovascular comorbidity (p=0.02) and initial severity of hearing loss (p=0.033) had a significant impact. Conclusions: Intratympanic corticosteroids have the same efficacy as systemic therapy in the treatment of primary ISSNHL and have positive safety profiles. Severe cases may be helped by combined therapy. In case of a failed systemic treatment, salvage intratympanic therapy works.

7 October 2026 in Children
Verified
Journal Article
Open access
PDF file
HMHannia Bertha Matt-Hernandez
Hannia Bertha Matt-Hernandez
MGMaria Isabel Rojo Gutierrez
Maria Isabel Rojo Gutierrez
Atopic dermatitis (AD) is a common chronic inflammatory skin disease in childhood characterized by pruritus, skin barrier dysfunction, and a relapsing–remitting course. Beyond its cutaneous manifestations, AD may substantially affect the psychosocial well-being of children and their families. Objective: To synthesize current evidence on the psychosocial burden of pediatric AD and integrate biopsychosocial and burden-of-disease frameworks into a clinically oriented approach, with particular relevance to pediatric allergy practice. Methods: A narrative review of literature published from January 2013 through May 2026 was conducted using PubMed/MEDLINE, Scopus, and Web of Science. Evidence addressing health-related quality of life, sleep disturbance, emotional and behavioral outcomes, social functioning, treatment-related burden, and caregiver and family burden was synthesized narratively, prioritizing pediatric populations. Results: Pediatric AD is associated with multidimensional burden involving health-related quality of life, sleep, emotional well-being, social functioning, and family life. Physician-assessed disease severity and patient- or family-perceived burden show imperfect correspondence, supporting the complementary use of patient- and caregiver-reported outcomes. Nocturnal pruritus and sleep disruption may contribute to bidirectional interactions among skin symptoms, emotional distress, and family burden. Visible lesions may contribute to stigma and social difficulties, while caregivers may experience sleep loss, stress, treatment burden, and concerns regarding topical corticosteroid use. Current guidance increasingly supports assessment of patient- and family-reported burden alongside objective disease severity. Conclusions: Integrating biopsychosocial and burden-of-disease perspectives may support a more comprehensive approach to pediatric AD. Routine care should include discussion of sleep, emotional well-being, social functioning, and family burden, with further assessment or multidisciplinary support considered when clinically relevant concerns are identified.